“Self-assembled monolayers (SAMs) of polyaminithiophenol (PATP) were used as a covalent bonded coating for solid-phase microextraction (SPME). Thiolated aniline-analog monomers (mixture of 2- and 3-aminothiophenols, 2/3-ATP) were anchored on the gold surface and then electropolymerized. Due to the strong
S-Au bond, thiol-terminated coating on the gold surface was very stable. The proposed covalent bonded coating showed higher mechanical (re-usability up to 100 times) and thermal stability (up to 320 A degrees C) than non-covalent bonded polyaniline coating (re-usability JQ-EZ-05 in vitro up to 20 times and thermal stability up to 250 A degrees C). The extraction capability of the proposed fiber for
the extraction of five polycyclic aromatic hydrocarbons (PAHs), including phenanthrene, anthracene, pyrene, 9,10-dimethylanthracene and benzo[alpha]anthracene was examined. The effects of different parameters S63845 molecular weight influencing the extraction efficiency of analytes including extraction temperature, extraction time, ionic strength, stirring rate and sample volume were examined and optimized. Linear ranges of 1-250 mu g L(-1) for phenanthrene and anthracene, and 1-100 mu g L(-1) for the other compounds were obtained. Detection limits were in the range of 0.1-0.32 mu g L(-1). Single fiber repeatability and fiber to fiber reproducibility were less than 8.9 and 15.8%, respectively. Seawater sample was analyzed as real sample and good recoveries (81-108%) were obtained for target p38 inhibitors clinical trials analytes.”
(EPO) receptor-mediated endocytosis and degradation in the bone marrow has been hypothesized to be the major clearance pathway of erythropoiesis-stimulating agents (ESA). We investigated the role of this pathway in ESA clearance by determining the pharmacokinetic profiles after intravenous (IV) dosing in rats and mice of recombinant human EPO (rHuEPO) and rHuEPO derivatives with different receptor binding activities and biochemical properties. These derivatives included NM385 (no detectable receptor binding activity), hyperglycosylated analogs with different carbohydrate contents and receptor binding activities; (NM294: +1 carbohydrate chain; darbepoetin alfa: +2 carbohydrate chains) and polyethylene glycol (PEG) derivatives (PEG-darbepoetin alfa, PEG-rHuFPO and PEG-NM385). After IV administration in rats, NM385 had a mean clearance (CL) similar to rHuEPO. Hyperglycosylated ESAs, compared with rHuEPO, had a progressively longer half-life (t(1/2)) and a progressively slower CL with increasing number of carbohydrates or amount of added PEG that correlated more closely with carbohydrate and/or PEG content than receptor binding activity.